.png)
koto_feja/E+ via Getty Images
- BeOne Medicines (NASDAQ:ONC) (OTCPK:BEIGF) said on Thursday that the European Commission has approved its monoclonal antibody therapy, Tevimbra (tislelizumab), in a combination regime for nasopharyngeal cancer.
- This treatment, used alongside gemcitabine and cisplatin, is intended for adults suffering from metastatic or recurrent
English (US) ·